Other formats:
BibTeX
LaTeX
RIS
@article{2281801,
author = {Libánská, A. and Randárová, E. and Skoroplyas, Svitlana and Bartoš, M. and Luňáčková, J. and Lager, F. and Renault, G. and Scherman, D. and Etrych, T.},
article_number = {January},
doi = {http://dx.doi.org/10.1016/j.jconrel.2022.11.027},
keywords = {Polymer conjugate; Drug delivery; Inflammation; HPMA; Dexamethasone; Collagen II -induced arthritis; Passive targeting},
language = {eng},
issn = {0168-3659},
journal = {Journal of Controlled Release},
title = {Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis},
url = {https://doi.org/10.1016/j.jconrel.2022.11.027},
volume = {353},
year = {2023}
}
TY - JOUR
ID - 2281801
AU - Libánská, A. - Randárová, E. - Skoroplyas, Svitlana - Bartoš, M. - Luňáčková, J. - Lager, F. - Renault, G. - Scherman, D. - Etrych, T.
PY - 2023
TI - Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis
JF - Journal of Controlled Release
VL - 353
IS - January
SP - 30-41
EP - 30-41
PB - Elsevier Science BV
SN - 01683659
KW - Polymer conjugate
KW - Drug delivery
KW - Inflammation
KW - HPMA
KW - Dexamethasone
KW - Collagen II -induced arthritis
KW - Passive targeting
UR - https://doi.org/10.1016/j.jconrel.2022.11.027
N2 - Chronic inflammatory diseases such as rheumatoid arthritis represent a substantial socio-economic impact and have a high prevalence in the modern world. Nano-sized polymer therapeutics have shown suitable characteristics for becoming the next generation of anti-inflammatory nanomedicines. Here, we present biocompatible and stimuli-sensitive N-(2-hydroxypropyl)methacrylamide based polymer conjugates with the anti-inflammatory drug dexamethasone (DEX), which has been tailored for prolonged blood circulation, enhanced inflammatory site accumulation, site-specific drug release and subsequent elimination of the carrier via urine excretion. The hydrodynamic size of novel polymer-DEX nanomedicine was adjusted to prolong its blood circulation whilst maintaining the renal excretability of the polymer carrier after drug release in inflamed tissue. The therapeutic efficacy of the studied polymer nanomedicines was evaluated in a model of dissipated chronic arthritis, i.e. collagen II-induced arthritis, in mice. The pH-sensitive drug attachment enabled enhanced blood circulation with minimal systemic drug release, as well as rapid drug activation in affected joints. Importantly, unlike free DEX, the polymer nanomedicines were able to diminish joint inflammation and arthritis-induced bone damage - even at a reduced dosing regimen - as evaluated by micro computed tomography (micro-CT).
ER -
LIBÁNSKÁ, A., E. RANDÁROVÁ, Svitlana SKOROPLYAS, M. BARTOŠ, J. LUŇÁČKOVÁ, F. LAGER, G. RENAULT, D. SCHERMAN and T. ETRYCH. Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis. \textit{Journal of Controlled Release}. Elsevier Science BV, 2023, vol.~353, January, p.~30-41. ISSN~0168-3659. Available from: https://dx.doi.org/10.1016/j.jconrel.2022.11.027.
|
